Toggle light / dark theme

Superlubricity and nanotechnology

Achieving near-zero friction in commercial and industrial applications will be game-changing from tiny microelectromechanical systems that will never wear out, to oil-free bearings in industrial equipment, to much more efficient engines and giant wind turbines scavenging energy even in low wind conditions. Superlubricity offers promising solutions to overcome lubrication challenges in various areas of nanotechnology including micro/nano-electromechanical systems (MEMS/NEMS), water transport control, biomedical engineering, atomic force microscopy (AFM), aerospace and wind energy applications, as well as other electronic devices. It is one of the most promising properties of functional nanomaterials for energy saving applications.

Europe bets R&D spending will bring jobs to battered economy

The European Union wants a massive dose of research spending to lift it out of what could be the worst recession in its history. Last week, as part of a €1.85 trillion budget and pandemic recovery proposal, the European Commission, the EU executive arm, unveiled plans to pump €94.4 billion into research over 7 years, nearly €11 billion more than originally planned for the program, called Horizon Europe. But not everyone thinks the money is the best medicine.


Horizon Europe gets €13.5 billion to spend fast, spur growth.

Up to 81% of COVID-19-Positive Patients are Asymptomatic: Study

In a paper published in the journal Thorax, a team of Australia researchers described the first instance of complete COVID-19 testing of all passengers and crew on an isolated cruise ship during the current pandemic: of the 217 passengers and crew on board, 128 tested positive for COVID-19 on reverse transcription-PCR; of the COVID-19-positive patients, only 24 (19%) were symptomatic.

Tiny Human Livers Grown in The Lab Have Been Successfully Transplanted Into Rats

Scientists have successfully transplanted functional miniature livers into rats, after growing the bioengineered organs in the lab from reprogrammed human skin cells.

The experiment, which gave the animals working liver organs, could lay the groundwork for future treatments to address terminal liver failure – a disease that claims the lives of over 40,000 people in the US every year.

While there’s still a lot of work to be done before the technique can directly aid human patients, the researchers say their proof of concept may help underpin a future alternative to liver transplants, which are often incredibly expensive procedures to perform, in addition to being strictly limited by donor supply.

Investigational COVID-19 Convalescent Plasma

Although promising, convalescent plasma has not yet been shown to be safe and effective as a treatment for COVID-19. Therefore, it is important to study the safety and efficacy of COVID-19 convalescent plasma in clinical trials.

Pathways for use of investigational COVID-19 convalescent plasma

The following pathways are available for administering or studying the use of COVID-19 convalescent plasma:

Fauci: Moderna COVID-19 Phase III Trial to Begin in July with 30,000 Patients

“That’s very early,” Anna Durbin, a vaccine researcher at Johns Hopkins University, told STAT. “We don’t know if those antibodies are durable.”

The Moderna press release also indicated that the antibody levels observed were equal to or greater in the 100 ug dose than was seen in patients who recovered from COVID-19. There’s not much context here, because studies on recovered COVID-19 patients have shown a range that is potentially influenced by the severity of the disease. For example, John “Jack” Rose, a Yale University vaccine researcher told STAT about a study in China demonstrating that in 175 recovered COVID-19 patients, 10 had no detectable neutralizing antibodies, while others had very high antibody levels.

Of the Phase III trial, Fauci indicated that the majority of trial participants will be between the ages of 18 and 55, but will include elderly Americans that are most at risk of serious illness from COVID-19.

/* */